Vascular endothelial cell growth factors (VEGFs) are secreted polypeptides with a highly conserved cystine-knot structure similar to that of the platelet-derived growth factors (PDGFs).  VEGFs play important roles in vascular development and in diseases involving abnormal growth of blood vessels such as tumor-related angiogenesis. VEGFs stimulate angiogenesis by binding to the specific receptors (VEGFRs) on the surface of vascular endothelial cells. All the three VEGFRs, VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1/CD309), and VEGFR3 (Flt-4), belong to the CSF-1/PDGF receptor subfamily of receptor tyrosine kinase superfamily (RTKs). Each VEGFR contains 7 immunoglobulin (Ig)-like C2-type domains in the extracellular region and an intracellular kinase domain. VEGFR1 is a receptor for VEGF, VEGFB and PDGF. VEGFR1 is expressed predominantly in normal lung and specifically expressed in most of the vascular endothelial cells and peripheral blood monocytes. VEGFR1 plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. It may act as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. VEGFR1 can promote endothelial cell proliferation, survival and angiogenesis in adulthood. VEGFR1 shows very high affinity for VEGF and relatively weak protein kinase activity.  VEGFR1 may function as a negative regulator of VEGF signaling by limiting the amount of free VEGF and preventing the binding to VEGFR2/KDR.

Vascular endothelial cell growth factors (VEGFs) are secreted polypeptides with a highly conserved cystine-knot structure similar to that of the platelet-derived growth factors (PDGFs).  VEGFs play important roles in vascular development and in diseases involving abnormal growth of blood vessels such as tumor-related angiogenesis. VEGFs stimulate angiogenesis by binding to the specific receptors (VEGFRs) on the surface of vascular endothelial cells. All the three VEGFRs, VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1/CD309), and VEGFR3 (Flt-4), belong to the CSF-1/PDGF receptor subfamily of receptor tyrosine kinase superfamily (RTKs). Each VEGFR contains 7 immunoglobulin (Ig)-like C2-type domains in the extracellular region and an intracellular kinase domain. VEGFR1 is a receptor for VEGF, VEGFB and PDGF. VEGFR1 is expressed predominantly in normal lung and specifically expressed in most of the vascular endothelial cells and peripheral blood monocytes. VEGFR1 plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. It may act as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. VEGFR1 can promote endothelial cell proliferation, survival and angiogenesis in adulthood. VEGFR1 shows very high affinity for VEGF and relatively weak protein kinase activity.  VEGFR1 may function as a negative regulator of VEGF signaling by limiting the amount of free VEGF and preventing the binding to VEGFR2/KDR.

 

Product Details

 

Gene Symbol: FLT1; VEGFR1; FLT; FLT-1; VEGFR-1; FRT

 

NCBI Gene ID: 2321

 

Uniprot Entry: P17948

 

Construct Details: Full length humanFLT1 gene (encoding Uniprot accession # P17948 - isoform 2 or soluble FLT1) is subcloned into the Lentiviral expression vector pLTC with an upstream CMV promoter, which can be used for both transient and stable expression in mammalian cells.  It can be co-transfected with the LentiPAK DNA mix (SKU# LP-001) into HEK293 cells to produce high titer lentiviral particles. 

 

Vector Type: pLTC (lentiviral expression vector containing a heterologous CMV promoter, see the vector map above)

 

Gene Insert Size: 2064 (bp)

 

Gene Insert Sequence:  

ATGGTCAGCTACTGGGACACCGGGGTCCTGCTGTGCGCGCTGCTCAGCTGTCTGCTTCTCACAGGATCTAGTTCAGGTTC

AAAATTAAAAGATCCTGAACTGAGTTTAAAAGGCACCCAGCACATCATGCAAGCAGGCCAGACACTGCATCTCCAATGCA

GGGGGGAAGCAGCCCATAAATGGTCTTTGCCTGAAATGGTGAGTAAGGAAAGCGAAAGGCTGAGCATAACTAAATCTGCC

TGTGGAAGAAATGGCAAACAATTCTGCAGTACTTTAACCTTGAACACAGCTCAAGCAAACCACACTGGCTTCTACAGCTG

CAAATATCTAGCTGTACCTACTTCAAAGAAGAAGGAAACAGAATCTGCAATCTATATATTTATTAGTGATACAGGTAGAC

CTTTCGTAGAGATGTACAGTGAAATCCCCGAAATTATACACATGACTGAAGGAAGGGAGCTCGTCATTCCCTGCCGGGTT

ACGTCACCTAACATCACTGTTACTTTAAAAAAGTTTCCACTTGACACTTTGATCCCTGATGGAAAACGCATAATCTGGGA

CAGTAGAAAGGGCTTCATCATATCAAATGCAACGTACAAAGAAATAGGGCTTCTGACCTGTGAAGCAACAGTCAATGGGC

ATTTGTATAAGACAAACTATCTCACACATCGACAAACCAATACAATCATAGATGTCCAAATAAGCACACCACGCCCAGTC

AAATTACTTAGAGGCCATACTCTTGTCCTCAATTGTACTGCTACCACTCCCTTGAACACGAGAGTTCAAATGACCTGGAG

TTACCCTGATGAAAAAAATAAGAGAGCTTCCGTAAGGCGACGAATTGACCAAAGCAATTCCCATGCCAACATATTCTACA

GTGTTCTTACTATTGACAAAATGCAGAACAAAGACAAAGGACTTTATACTTGTCGTGTAAGGAGTGGACCATCATTCAAA

TCTGTTAACACCTCAGTGCATATATATGATAAAGCATTCATCACTGTGAAACATCGAAAACAGCAGGTGCTTGAAACCGT

AGCTGGCAAGCGGTCTTACCGGCTCTCTATGAAAGTGAAGGCATTTCCCTCGCCGGAAGTTGTATGGTTAAAAGATGGGT

TACCTGCGACTGAGAAATCTGCTCGCTATTTGACTCGTGGCTACTCGTTAATTATCAAGGACGTAACTGAAGAGGATGCA

GGGAATTATACAATCTTGCTGAGCATAAAACAGTCAAATGTGTTTAAAAACCTCACTGCCACTCTAATTGTCAATGTGAA

ACCCCAGATTTACGAAAAGGCCGTGTCATCGTTTCCAGACCCGGCTCTCTACCCACTGGGCAGCAGACAAATCCTGACTT

GTACCGCATATGGTATCCCTCAACCTACAATCAAGTGGTTCTGGCACCCCTGTAACCATAATCATTCCGAAGCAAGGTGT

GACTTTTGTTCCAATAATGAAGAGTCCTTTATCCTGGATGCTGACAGCAACATGGGAAACAGAATTGAGAGCATCACTCA

GCGCATGGCAATAATAGAAGGAAAGAATAAGATGGCTAGCACCTTGGTTGTGGCTGACTCTAGAATTTCTGGAATCTACA

TTTGCATAGCTTCCAATAAAGTTGGGACTGTGGGAAGAAACATAAGCTTTTATATCACAGATGTGCCAAATGGGTTTCAT

GTTAACTTGGAAAAAATGCCGACGGAAGGAGAGGACCTGAAACTGTCTTGCACAGTTAACAAGTTCTTATACAGAGACGT

TACTTGGATTTTACTGCGGACAGTTAATAACAGAACAATGCACTACAGTATTAGCAAGCAAAAAATGGCCATCACTAAGG

AGCACTCCATCACTCTTAATCTTACCATCATGAATGTTTCCCTGCAAGATTCAGGCACCTATGCCTGCAGAGCCAGGAAT

GTATACACAGGGGAAGAAATCCTCCAGAAGAAAGAAATTACAATCAGAGGTGAGCACTGCAACAAAAAGGCTGTTTTCTC

TCGGATCTCCAAATTTAAAAGCACAAGGAATGATTGTACCACACAAAGTAATGTAAAACATTAA

 

Formulation: Lentivector encoded and pre-packaged viral particles (typical titer 10⁶ - 10⁷ IFU/ml) in the conditional medium (serum-free) from HEK293 cells that have been transfected with the lentivector gene clone and the LentiPAK DNA mix

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Important Safety Information: With the safety features in place, our lentiviral vectors and viral particles can be employed in standard Biosafety Level 2 tissue culture facilities and should be treated with the same level of caution as any other potentially infectious agent. Any investigator who purchases our lentiviral/retroviral products & services is responsible for following Biosafety Level 2 requirements on the handling of viral particles. For more information on Biosafety Level 2 agents and practices, please refer to NIH’s “Biosafety Considerations for Research with Lentiviral Vectors”.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C for immediate use.  Upon receipt, centrifuge the vial briefly before opening.  Store at –80°C or lower and the product is stable for 3 months.  Avoid repeated freeze-thaw cycles.

 

 

The product should be employed in a Biosafety Level 2 tissue culture facility.

 

 

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Proc. Natl. Acad. Sci. USA. 90:10705 (1993).

2. J. Mol. Biol. 293:531 (1999).

3. J Biol Chem. 283 (37):25404 (2008).

4. Nature 376:66 (1995).  

5. N. Engl. J. Med. 350:672 (2004). 

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: LTV1058-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.